216 related articles for article (PubMed ID: 14557424)
1. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
Plotkin H; Rauch F; Zeitlin L; Munns C; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2003 Oct; 88(10):4569-75. PubMed ID: 14557424
[TBL] [Abstract][Full Text] [Related]
2. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
Pfeilschifter J; Ziegler R
Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Chapurlat RD; Delmas PD; Liens D; Meunier PJ
J Bone Miner Res; 1997 Oct; 12(10):1746-52. PubMed ID: 9333137
[TBL] [Abstract][Full Text] [Related]
4. Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia.
Isaia GC; Lala R; Defilippi C; Matarazzo P; Andreo M; Roggia C; Priolo G; de Sanctis C
Calcif Tissue Int; 2002 Aug; 71(2):121-8. PubMed ID: 12200645
[TBL] [Abstract][Full Text] [Related]
5. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
[TBL] [Abstract][Full Text] [Related]
6. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
[TBL] [Abstract][Full Text] [Related]
7. Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood.
Chan B; Zacharin M
J Pediatr Endocrinol Metab; 2006 Jan; 19(1):75-80. PubMed ID: 16509531
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia.
Parisi MS; Oliveri B; Mautalen CA
Bone; 2003 Oct; 33(4):582-8. PubMed ID: 14555262
[TBL] [Abstract][Full Text] [Related]
9. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
Lala R; Matarazzo P; Bertelloni S; Buzi F; Rigon F; de Sanctis C
Acta Paediatr; 2000 Feb; 89(2):188-93. PubMed ID: 10709889
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.
Corsi A; Ippolito E; Robey PG; Riminucci M; Boyde A
Skeletal Radiol; 2017 Oct; 46(10):1435-1439. PubMed ID: 28660402
[TBL] [Abstract][Full Text] [Related]
11. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome.
Zacharin M; O'Sullivan M
J Pediatr; 2000 Sep; 137(3):403-9. PubMed ID: 10969268
[TBL] [Abstract][Full Text] [Related]
12. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
13. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
14. Bone mineralization in polyostotic fibrous dysplasia: histomorphometric analysis.
Terpstra L; Rauch F; Plotkin H; Travers R; Glorieux FH
J Bone Miner Res; 2002 Nov; 17(11):1949-53. PubMed ID: 12412801
[TBL] [Abstract][Full Text] [Related]
15. Medical therapy in adults with fibrous dysplasia of bone.
Chapurlat RD
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P114-9. PubMed ID: 17228999
[TBL] [Abstract][Full Text] [Related]
16. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism.
Rauch F; Plotkin H; Travers R; Zeitlin L; Glorieux FH
J Clin Endocrinol Metab; 2003 Mar; 88(3):986-92. PubMed ID: 12629073
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome.
Lala R; Matarazzo P; Andreo M; Marzari D; Bellone J; Corrias A; de Sanctis C;
J Pediatr Endocrinol Metab; 2006 May; 19 Suppl 2():583-93. PubMed ID: 16789621
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Liens D; Delmas PD; Meunier PJ
Lancet; 1994 Apr; 343(8903):953-4. PubMed ID: 7909013
[TBL] [Abstract][Full Text] [Related]
19. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy.
Rauch F; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2006 Feb; 91(2):511-6. PubMed ID: 16291701
[TBL] [Abstract][Full Text] [Related]
20. [Fibrous dysplasia: differential diagnosis from Paget's disease].
Wagner P; Heilmann P; Schulz A; Nawroth P; Kasperk Ch
Dtsch Med Wochenschr; 2002 Oct; 127(43):2264-8. PubMed ID: 12397541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
